Valneva SE Expected to Earn FY2024 Earnings of $0.00 Per Share (NASDAQ:VALN)

Valneva SE (NASDAQ:VALN) – HC Wainwright lowered their FY2024 EPS estimates for shares of Valneva in a research note issued on Friday, October 11th. HC Wainwright analyst E. White now forecasts that the company will post earnings of $0.00 per share for the year, down from their prior estimate of $0.02. HC Wainwright has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for Valneva’s current full-year earnings is $0.02 per share.

Valneva Stock Performance

Shares of NASDAQ VALN opened at $5.55 on Monday. Valneva has a 12-month low of $5.49 and a 12-month high of $14.49. The firm has a market capitalization of $386.49 million, a price-to-earnings ratio of -13.54 and a beta of 2.17. The company has a current ratio of 2.63, a quick ratio of 2.15 and a debt-to-equity ratio of 0.97. The firm has a 50 day moving average of $6.72 and a 200 day moving average of $7.41.

Valneva (NASDAQ:VALN) last posted its earnings results on Tuesday, August 13th. The company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.02. The company had revenue of $40.97 million for the quarter, compared to the consensus estimate of $46.83 million. Valneva had a negative return on equity of 20.01% and a negative net margin of 21.31%.

Institutional Investors Weigh In On Valneva

An institutional investor recently raised its position in Valneva stock. AlphaCentric Advisors LLC lifted its position in shares of Valneva SE (NASDAQ:VALN) by 42.3% during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 88,252 shares of the company’s stock after buying an additional 26,248 shares during the quarter. AlphaCentric Advisors LLC owned approximately 0.13% of Valneva worth $649,000 at the end of the most recent quarter. Institutional investors own 11.39% of the company’s stock.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.